|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.300 SEK | -2.26% |
|
-5.25% | -34.01% |
| 07-08 | Irlab board member James Gamgort buys shares for just under SEK 0.3m | FW |
| 06-30 | IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors | CI |
Company Valuation: IRLAB Therapeutics AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,277 | 1,987 | 389 | 557.6 | 167.3 | 197.8 | - |
| Change | - | -12.75% | -80.42% | 43.33% | -69.99% | 18.2% | - |
| Enterprise Value (EV) | 1,875 | 1,734 | 277.7 | 494.2 | 167.3 | 197.8 | 197.8 |
| Change | - | -7.53% | -83.98% | 77.96% | -66.14% | 18.2% | 0% |
| P/E | 44x | -17.5x | -2.19x | -6.72x | - | - | - |
| PBR | - | 6.83x | - | 17.1x | - | - | - |
| PEG | - | 0x | -0x | 0.1x | - | - | - |
| Capitalization / Revenue | 11x | 32.5x | 68.5x | 5.89x | 2.91x | 1.94x | 1.39x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.94x | 1.39x |
| EV / EBITDA | 0x | -0x | -0x | -0x | -0x | -7.17x | 5.3x |
| EV / EBIT | 0x | -0x | -0x | -0x | -0x | -6.26x | 5.94x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | 1 | -2.19 | -3.43 | -1.6 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 207.8 | 61.14 | 5.678 | 94.63 | 57.46 | 102 | 141.8 |
| EBITDA 1 | 56.05 | -108.3 | -176.4 | -70.53 | -89.08 | -27.6 | 37.3 |
| EBIT 1 | 52.58 | -113.1 | -180.8 | -75.11 | -93.4 | -31.6 | 33.3 |
| Net income 1 | 51.78 | -113.4 | -177.8 | -83.13 | -110 | -32.6 | 33.3 |
| Net Debt | -401.9 | -252.8 | -111.3 | -63.38 | - | - | - |
| Reference price 2 | 44.000 | 38.300 | 7.500 | 10.750 | 1.970 | 1.330 | 1.330 |
| Nbr of stocks (in thousands) | 51,748 | 51,868 | 51,868 | 51,868 | 84,938 | 148,712 | - |
| Announcement Date | 2/23/22 | 2/23/23 | 2/7/24 | 2/12/25 | 2/25/26 | - | - |
1SEK in Million2SEK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 20.41M | |
| 34.57x | 12.36x | 25.86x | 0.58% | 1,037B | |
| 27.4x | 6.26x | 17.33x | 2.1% | 615B | |
| 33x | 7.49x | 15.4x | 2.71% | 448B | |
| 17.76x | 4.4x | 10.85x | 3.01% | 326B | |
| 21.11x | 5.63x | 13.79x | 2.84% | 293B | |
| 21.21x | 4.47x | 12.37x | 1.97% | 264B | |
| 14.09x | 5.24x | 10.8x | 3.55% | 216B | |
| 24.01x | 6.34x | 11.18x | 2.76% | 198B | |
| -46.95x | 5.62x | 31.09x | 2.53% | 162B | |
| Average | 16.24x | 6.43x | 16.52x | 2.45% | 355.75B | |
| Weighted average by Cap. | 23.96x | 7.75x | 18.21x | 2.01% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IRLAB A Stock
- Valuation IRLAB Therapeutics AB
Select your edition
All financial news and data tailored to specific country editions
